Open original FDA record ↗Recall record
- FDA identifier
- Z-0218-2019
- Company in FDA record
- BioMerieux SA
- FDA record creation date
- Oct 23, 2018
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Data loggers showed that one shipment to the United States experienced low temperatures that may impact performance of this product.
Source facts
- Action
- bioMerieux notified customers on about 09/17/2018 via "URGENT PRODUCT REMOVAL NOTICE". Instructions included the following. 1. Confirm this information has been distributed to, and reviewed by, all appropriate personnel within your organization. Retain a copy of this letter for your files, and forward this information to all parties that may use this product, including others to whom you may have transferred this product. 2. Please discontinue use and destroy any impacted product remaining in your local inventory and contact your local bioMrieux, Inc. representative for credit. 3. Among tests previously performed with these batches, we advise you to discuss patients results: identify any possible false results, retest impacted samples when possible, analyze the related risks and determine appropriate actions if relevant. 4. Complete the attached Acknowledgement Form in Attachment A to confirm receipt of this notice and return it to your local bioMrieux, Inc. representative. Questions and concerns can be directed to Clinical Customer Service representative at (800) 682-2666 or Industry Customer Service representative at (800) 634-7656.
- Initiated
- 2018-09-17
- Root cause
- Other
- Terminated
- 2020-05-18
- Distribution
- Nationwide distribution to MD, TX, MA, GA, OH, OR, CA, and WA.
- Recall number
- Z-0218-2019
- Recall status
- Terminated
- CDRH record ID
- 167420
- FDA record created
- 2018-10-23
- Recall event number
- 81067